For example, efficacies up to 70% for classical Hodgkin lymphoma,96 60% for advanced Merkel-cell carcinoma,97 and good overall results for urothelial carcinoma have been reported.98 Indeed, PD-L1/PD-1 immune checkpoint inhibitors are approved for first-line use in melanoma.99 However, a significant number of patients do not respond to these therapies. The gene discussed is CD274; the disease is melanoma.